BUSINESSWEEK'S HOT GROWTH COMPANIES

Hot Growth Special Report 2006 >

Untitled


92

AngioDynamics (ANGO)

This company's devices span the gamut of medical care, with some products that help make patients look better and others that play life-saving roles in treating the acutely ill. AngioDynamics makes guidewires, imaging machines and other devices that physicians use to clear clogged arteries, and catheters that help them treat patients with kidney failure. One of the company's fastest-growing product lines is VenaCure, which consists of lasers that erase unsightly varicose veins. As the population of Baby Boomers continues to age, demand for cosmetic procedures is soaring, and that's evident in AngioDynamics's recent financial results: in the quarter ended February 25, sales of venous products skyrocketed 81% to $1.4 million over the same period in 2005. Net sales jumped 28% to $19.8 million and profits leapt 73% to $1.9 million.

Company Info

2005 Rank

93

Market Value*
($ Millions)

386.3

Sales*
($ Millions)

72.2

Sales Growth
(3-yr. avg. annual)

23.3 %

Profits*
($ Millions)

6.5

Profit Growth
(3-yr. avg. annual)

72.8 %

Return on Inv. Capital (3-yr.)

9.1 %

Share Price
12-Mo. Hi/Lo

31/17

Share Price
As of 4/28/06

31

Return on Equity

11.3 %

P/E Ratio

62

No. of Employees

300

Industry Health Care Equipment
CURRENT
MARKET INFO

ANGO >

COMPANY WEB SITE >
Location Queensbury, N.Y.
Phone 518 798-1215
*Trailing 12 months
Stock price data as of 4/28/06
DATA: Standard & Poor's Compustat

Related Articles

Toyota Plans 10% Rise In Output


Company Snapshot

AngioDynamics engages in the design, development, manufacture, and marketing of medical devices for the minimally invasive diagnosis and treatment of peripheral vascular disease. Its products include angiographic catheters, hemodialysis catheters, plasma thromboplastin antecedent dilation catheters, thrombolytic products, image-guided vascular access products, endovascular laser venous system products, and drainage products. The company's therapeutic and diagnostic devices enable interventional radiologists, vascular surgeons, and others to treat peripheral vascular diseases and other noncoronary diseases. AngioDynamics sells its products primarily in the U.S., Europe, and Japan. The company was co-founded by Eamonn P. Hobbs in 1988. It was formerly known as A.D., Inc. and changed its name to AngioDynamics, Inc. in 1996. AngioDynamics has its headquarters in Queensbury, N.Y.


Data provided by Capital IQ
 
Eamonn P. Hobbs

Eamonn P. Hobbs, 46

Chief Executive Officer, Preident and Director


Total Compensation*

$ 728,539

Total Options Value*

$ 6,916,691

* Fiscal Year 2005

DEGREES HELD
University of Massachusetts Lowell - BS


Executive Bio

Eamonn Hobbs has served as president and CEO of AngioDynamics since June, 1996, and was a co-founder. Hobbs served as vice-president, AngioDynamics, of E-Z-EM from 1991 to October, 2002. He was first employed by E-Z-EM from 1985 to 1986 and was continuously employed by the company from 1988. Hobbs is a biomedical engineer with more than 23 years experience in the interventional radiology, interventional cardiology, and the gastroenterology medical-device industries. From 1986 to 1988, Hobbs served as a director of marketing for North American Instrument, a medical device company since acquired by Boston Scientific. He is the only business executive from the medical-device industry to serve on the strategic planning committee of the Society of Interventional Radiology, and is a frequent lecturer on the future of interventional radiology and interventional radiology practice. He holds a BS in plastics engineering with a biomaterials emphasis from the University of Lowell.


Management Team

Key Executives

Eamonn P. Hobbs; Paul J. Shea; Daniel K. Recinella; Robert M. Rossell; Harold C. Mapes; Brian S. Kunst; Joseph G. Gerardi; William M. Appling

Board Directors

Eamonn Hobbs (CEO); Paul Echenberg (Chairman); Peter J. Graham; Gregory D. Casciaro; Howard Donnelly; Robert E. Flaherty; Jeffery Gold; David Meyers; Dennis S. Meteny


Executive Data provided by Capital IQ